Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy

Published:January 07, 2019DOI:


      This study evaluated patients, treatment, or disease characteristics that could predict response to stereotactic body radiation therapy (SBRT) and survival in a database of patients with oligometastatic disease from different solid tumors.

      Methods and Materials

      Patients treated with SBRT for oligometastatic disease between 2014 and 2015 were included. Patients were defined as oligometastatic if they were affected by a maximum of 5 active lesions in 3 different sites. They had to be treated with SBRT with radical intent.


      The study included 358 patients. With a median follow-up of 31.83 months, local control at 6 and 24 months was 94.6% and 78.9%, respectively. Distant progression was recorded in 279 patients (77.9%). Progression-free survival at 6 and 24 months was 66.1% and 18.4%, respectively. At last follow-up, 195 patients (54.5%) were still alive in 59 cases with no evidence of disease. The median overall survival (OS) was 34.7 months (95% confidence interval, 29.66-43.83). OS at 6 and 24 months was 96.07% and 63.57%, respectively. On multivariable analysis, the presence of lung metastases (hazard ratio [HR], 0.50 [0.33-0.75]; P = .001) and nodal metastases (HR, 0.44 [0.24-0.78]; P = .005) was related to longer OS. Primary lung cancer (HR, 1.89 [1.14-3.13]; P = .013), increasing age (HR, 1.02 [1.01-1.04]; P = .002), and the presence of metastatic sites other than the irradiated ones (HR, 2.19 [1.39-3.43]; P = .001) were all independent predictors of shorter OS. Local response was associated with OS.


      SBRT for patients with oligometastatic disease is effective. Local response is strongly correlated with patients'’ prognosis, also underlying its relevance in a metastatic setting.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hellman S.
        • Weichselbaum R.R.
        J Clin Oncol. 1995; 13: 8-10
        • Potters L.
        • Kavanagh B.
        • Galvin J.M.
        • et al.
        American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of Stereotactic Body Radiation Therapy.
        Int J Radiat Oncol Biol Phys. 2010; 76: 326-332
        • Tree A.C.
        • Khoo V.S.
        • Eeles R.A.
        • et al.
        Stereotactic body radiotherapy for oligometastases.
        Lancet Oncol. 2013; 14: e28-e37
        • Katz A.W.
        • Carey-Sampson M.
        • Muhs A.G.
        • et al.
        Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases.
        Int J Radiat Oncol Biol Phys. 2007; 67: 793-798
        • Rusthoven K.E.
        • Kavanagh B.D.
        • Burri S.H.
        • et al.
        Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases.
        J Clin Oncol. 2009; 27: 1579-1584
        • Okunieff P.
        • Petersen A.L.
        • Philip A.
        • et al.
        Stereotactic Body Radiation Therapy (SBRT) for lung metastases.
        Acta Oncol. 2006; 45: 808-817
        • Chang E.L.
        • Shiu A.S.
        • Mendel E.
        • et al.
        Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure.
        J Neurosurg Spine. 2007; 7: 151-160
        • Chawla S.
        • Chen Y.
        • Katz A.W.
        • et al.
        Stereotactic body radiotherapy for treatment of adrenal metastases.
        Int J Radiat Oncol Biol Phys. 2009; 75: 71-75
        • Torok J.
        • Wegner R.E.
        • Burton S.A.
        • Heron D.E.
        Stereotactic body radiation therapy for adrenal metastases: A retrospective review of a noninvasive therapeutic strategy.
        Future Oncol. 2011; 7: 145-151
        • Milano M.T.
        • Katz A.W.
        • Zhang H.
        • Okunieff P.
        Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study.
        Int J Radiat Oncol Biol Phys. 2012; 83: 878-886
        • Salama J.K.
        • Hasselle M.D.
        • Chmura S.J.
        • et al.
        Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.
        Cancer. 2012; 118: 2962-2970
        • Kao J.
        • Packer S.
        • Ha L.V.
        • et al.
        Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: Acute toxicity and preliminary response.
        Cancer. 2009; 115: 3571-3580
        • Fode M.M.
        • Høyer M.
        Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases.
        Radiother Oncol. 2015; 114: 155-160
        • Hoyer M.
        • Roed H.
        • Traberg Hansen A.
        • et al.
        Phase II study on stereotactic body radiotherapy of colorectal metastases.
        Acta Oncol. 2006; 45: 823-830
        • de Vin T.
        • Engels B.
        • Gevaert T.
        • Storme G.
        • De Ridder M.
        Stereotactic radiotherapy for oligometastatic cancer: A prognostic model for survival.
        Ann Oncol. 2014; 25: 467-471
        • Wong A.C.
        • Watson S.P.
        • Pitroda S.P.
        • et al.
        Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).
        Cancer. 2016; 122: 2242-2250
        • Hong J.C.
        • Ayala-Peacock D.N.
        • Lee J.
        • et al.
        Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
        PLoS One. 2018; 13: e0195149
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Helou J.
        • Thibault I.
        • Poon I.
        • et al.
        Stereotactic ablative radiation therapy for pulmonary metastases: Histology, dose, and indication matter.
        Int J Radiat Oncol Biol Phys. 2017; 98: 419-427
        • Franceschini D.
        • Cozzi L.
        • De Rose F.
        • et al.
        Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours.
        J Cancer Res Clin Oncol. 2017; 143: 1293-1299
        • Xu Q.
        • Zhou F.
        • Liu H.
        • et al.
        Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs.
        J Thorac Oncol. 2018; 13: 1383-1392
        • Pembroke C.A.
        • Fortin B.
        • Kopek N.
        Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression.
        Radiother Oncology. 2018; 127: 493-500


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.